New wholly owned subsidiary, led by commercial appointment Adrian Jones, to expand the Company’s network of clinics and pharmacies across Australia
Vancouver, British Columbia— Optimi Health Corp. (Nasdaq: OPTH, CSE: OPTI, FSE: 8BN) (the “**Company**” or “**Optimi**”), a commercial-stage pharmaceutical developer and manufacturer of regulated psychedelic drug products, today announced the establishment of Optimi Australia Pty Ltd (“**Optimi Australia**”), a wholly owned subsidiary responsible for distribution and business development in Australia, and the appointment of Adrian Jones as Director of Australian Operations.
Optimi Australia will handle the Company’s sales, distribution, and prescriber relationships across the country. It will sell Optimi’s finished drug products, 5mg naturally derived psilocybin capsules and 40mg and 60mg MDMA capsules, to clinics and pharmacies under Australia’s Authorised Prescriber Scheme. All products are manufactured at the Company’s Health Canada-licensed GMP facility in Princeton, British Columbia.
Mr. Jones joins Optimi after more than 15 years at Bristol Myers Squibb, most recently as Associate Director, Head of Sales and Marketing for its Australian oncology and cardiovascular portfolios, where he led national commercial teams and served as launch lead for first-in-class therapies including Opdivo and Camzyos. His early career includes psychiatry roles with Eli Lilly, BMS and Hospira.
“Australia is our first commercial market and the opportunity there is compounding,” said Dane Stevens, Chief Executive Officer of Optimi. “Optimi Australia puts our team on the ground, and in Adrian we have a leader who has launched new therapies in this market for twenty-five years.”
“My immediate focus is to understand the needs of the clinicians and to help them deliver therapy as efficiently and effectively as possible.” said Adrian Jones, Director of Australian Operations. “Authorised prescribers, clinics, and pharmacies seeking product information, documentation, or account setup can contact me directly at adrian@optimihealth.ca.”
More information is available at the Company’s Australian website, www.optimi.com.au.
About Optimi Health Corp.
Optimi Health Corp. (Nasdaq: OPTH, CSE: OPTI, FSE: 8BN) is a commercial-stage pharmaceutical company focused on developing, manufacturing, and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada.
Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorised Prescriber Scheme and accessible in Canada through the Special Access Program. The Company is advancing a Health Canada-approved Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder and a proposed Phase 3 clinical trial evaluating MDMA-assisted therapy for post-traumatic stress disorder. Learn more at www.optimi.net.
Company Contact:
Dane Stevens, Chief Executive Officer
Telephone: (778) 761-4551
investors@optimi.net
Australian Inquiries:
Adrian Jones
Director of Australian Operations – Psychedelics
Optimi Health Australia
E. adrian@optimihealth.ca
M. +61 (0) 408 117 700
